ArticleJournal of translational medicine2024
Triglyceride-glucose index and glycemic dynamics in pancreatic ductal adenocarcinoma: implications for disease progression and prognosis.
Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Relationships of triglyceride-glucose-related indices with colorectal cancer incidence and mortality in an American population: a dose-response meta-analysis and cohort study.Lipids in health and disease · 2025Pooled it
- Pancreatic cancer-associated organ dysfunction promotes muscle autophagy and contributes to peripheral tissue wasting.bioRxiv : the preprint server for biology · 2026Article
- Reduced lipid metabolite abundance in human pancreatic cancer and matched serum samples following neoadjuvant FOLFIRINOX treatment.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- "Paradoxical" prognostic role of the TyG index and a novel machine learning-derived nomogram for colorectal cancer liver metastases.Frontiers in nutrition · 2026Article
- Reciprocal mediation of immuno-inflammation and insulin resistance in the risk of chronic kidney disease among patients with coronary artery disease: insights from neutrophil-to-lymphocyte ratio and triglyceride-glucose index.Frontiers in immunology · 2026Article
- Independent prognostic value of the triglyceride-glucose index and its incremental predictive contribution beyond traditional risk markers in acute heart failure: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Association of four non-insulin-based insulin resistance surrogate markers with colorectal cancer risk: a large-scale prospective cohort study using the UK Biobank.Frontiers in endocrinology · 2026Article
- From metabolic syndrome to survival: a prognostic model for PDAC incorporating insulin resistance markers and pathological variables.Frontiers in endocrinology · 2026Article
- An interpretable machine learning model for predicting distant organ metastasis after radical resection of colorectal cancer.Frontiers in oncology · 2026Article
- The correlation between the triglyceride-glucose index and the odds of cervical cancer.Frontiers in oncology · 2026Article
- Association between triglyceride-glucose index and intracranial aneurysm rupture: findings from a retrospective study.Neurosurgical review · 2025Observational
- Triglyceride-glucose index in predicting gastric cancer prognosis: A need for caution.World journal of gastroenterology · 2025Article
- Triglyceride glucose index - body mass index predicts insulin resistance, metabolic syndrome and associates with impaired ovulation in Chinese women with polycystic ovary syndrome.Frontiers in endocrinology · 2025Article
- The triglyceride-glucose index associated with reduced risk of liver metastasis in pancreatic cancer.Frontiers in endocrinology · 2025Article
- Comparative study on the predictive value of TyG, TyG-BMI, and TG/HDL-C for progression-free survival in patients with locally advanced nasopharyngeal carcinoma.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo elucidate the relationship between the triglyceride-glycemic index (TyG) and clinical characteristics of pancreatic ductal adenocarcinoma (PDAC).
methodsA total of 1,594 individuals diagnosed with pancreatic and periampullary neoplasms were categorized into four groups: PDAC-early (n = 403), locally advanced PDAC (LAPC, n = 315), PDAC-late with distant metastasis (n = 371), and other tumor types (n = 505). TyG-high was defined as a TyG index greater than 8.81 in males and 8.73 in females.
resultsThe prevalence of TyG-high status was highest in PDAC-early (68.48%), followed by LAPC (53.33%), and lowest in PDAC-late (44.47%). TyG-high status significantly predicted worse PDAC prognosis (P = 0.0166), particularly in PDAC-late (P = 0.0420). Despite similar blood glucose levels across PDAC groups (P = 0.897), PDAC-early patients showed significantly higher rates of glycemic disturbances (56.33% vs. 32.28%) and TyG-high status (68.48% vs. 47.13%) compared to those with other tumors. Progressive increases in glycemic disturbances and TyG-high status were observed from benign to pre-malignant lesions and PDAC-early. PDAC-early patients at the pancreatic head exhibited higher rates of glycemic disturbances (58.12% vs. 33.33%, P < 0.0001), larger pancreatic duct diameters (0.4056 cm vs. 0.3398 cm, P = 0.0043), and poorer prognosis compared to periampullary cancers, although the TyG-high rate and body mass index were similar.
conclusionThe TyG index exhibits a complex association with PDAC stages, profoundly shaping glycemic profiles. At the initial stages of PDAC, a notable elevation in TyG-high status and glycemic disturbances is observed. However, in advanced PDAC, while the TyG-high rate diminishes, abnormal glucose levels persist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.